Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Polycystic Ovary Syndrome 9Neoplasms 5Endometrial Neoplasms 3Prostatic Neoplasms 2Peripheral Nervous System Diseases 2Obesity 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Leukemia, Myeloid, Acute 2Leiomyoma 2Insulin Resistance 2Inflammation 2Infertility, Female 2Glioblastoma 2Diabetes Mellitus 2Colorectal Neoplasms 2Cognitive Dysfunction 2Cardiotoxicity 2Weight Gain 1Vomiting 1Venous Thromboembolism 1Vascular Malformations 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Tablets × Clear all
NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
182 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡